(Q36253605)

13 August 2017

1 reference

title

Is intravesical chemotherapy for superficial bladder cancer still justified? (English)

1 reference

13 August 2017

1 reference

1 reference

Aloysius A Okeke

1

1 reference

13 August 2017

John L Probert

series ordinal

2

1 reference

13 August 2017

David A Gillatt

series ordinal

3

1 reference

13 August 2017

Hartwig Schwaibold

series ordinal

4

1 reference

13 August 2017

publication date

1 October 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

96

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

763-767

1 reference

Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05711.X

Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05711.X

Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05711.X

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05711.X

Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer geni

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05711.X

Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05711.X

The treated natural history of high risk superficial bladder cancer: 15-year outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05711.X

Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05711.X

10.1111/J.1464-410X.2005.05711.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference